Median PFS was 177 months ( 95 % CI 147-not reached ) for the women treated with cediranib plus olaparib compared with 90 months ( 95 % CI 57-165 ) for those treated with olaparib monotherapy ( hazard ratio 042 , 95 % CI 023-076 ; p = 0005 ) .